Ms. Alon is a key leader in the venture capital, life sciences, healthcare and medical devices industries in Israel, with over 35 years of expertise, know-how and business management experience. Ms. Alon is the Founder and CEO of Medstrada; a company established in 2018, providing consulting services to the healthcare and food-tech industries. Ms. Alon also served as General Partner at the Pitango Venture Capital Fund and headed the Life Sciences sector. Among other things, Ms. Alon lead portfolio companies to successful acquisitions, including Disc-O-Tech, Colbar, Ventor and Optonol, where she served as a director. Ms. Alon currently serves as a director in many companies in the Healthcare Industry, including: Brainsgate, Carbofix Orthopedics, Vascular Biogenics (VBLT), Anchiano Therapeutics (ANCN) which are traded on Nasdaq, as well as a Director at BioRap, Tech Transfer Office of the Rappaport Institute, Technion.
Ms. Alon initiated and led the establishment in 2005, of ILSI (the Israeli Life Sciences Industry Association), a non-profit organization representing the common goals of approximately 1,200 Israeli life sciences companies. Ms. Alon is also the co-founder of IATI, (the Israeli Advanced Industries Association), the umbrella organization of the high-tech, life sciences and other advanced industries in Israel, established in 2012. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. in business administration from Boston University and an M.Sc. from Columbia University, School of Physicians and Surgeons.
Ronen Twito CPA
Co-Chairperson of the Board
Mr. Twito brings with him over 20 year of financial and managerial experience, executive positions and investor in NASDAQ and TASE listed companies. Mr. Twito is the founder of Amplify Capital Ltd. He led multiple IPOs, and follow on offerings, strategic licensing and collaboration agreements mainly within the biotech and technology spaces such as XTL Biopharmaceuticals “XTLB“, Cellect Biotechnology “APOP”, BioBlast pharma “ORPN”, “MTSL”. Prior to that, served at a global Telecom company listed on London LSE and as a senior manager at EY. Ronen is a Certified Public Accountant (CPA), Israel, He has a B.A. in Business and Management: Major - Accounting from Management College (The
Michlala L’Minhal Collman) Ronen is a member of the Institute of CPAs in Israel.
Prof. Michel Revel, MD, PhD
Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.
In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.
Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.
Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.
Mr Olivier SAMUEL has been running a consulting activity since 2001, in operational and strategic project management specialized in the field of health, in particular in the fields of geriatric care and healthcare management on behalf of leading operators and brands in the field of medical equipment, retirement homes, telecommunication operators, health insurance and investment funds.
He has been a member of the board of Kadimastem since 2010 on behalf of Mr Julien Ruggierie.
Mr. Samuel is a graduate of EM Lyon and the Lille School of Health Engineers.
Mr. Samuel has been the CEO from 1997 to 2020 was the CEO of Adomsante in France. company specialized in home care and medical equipment for the elderly in France.
Anat Tsour Segal
Anat joined Capital Nature in 2018. Anat brings expertise in venture creation and development, corporate finance and investment management, with strong focus on innovation. Prior to joining Capital Nature in 2018, Ms. Tsour Segal has executed and managed venture capital and private equity investments for sizable global investors, concentrating in technology, life science, clean-tech, and cyber security. From 2003 – 2016 Ms. Tsour Segal has founded and served as CEO of Xenia Venture Capital, a leading publicly traded (TASE) Israeli seed stage Investment company and a technological incubator. Under Ms. Tsour Segal’s guidance, Xenia has seeded over 20 companies that have reached a cumulative value of over $1 Billion and attained several successful exits. Ms. Tsour Segal was also Managing Director & Head of Corporate Finance of Tamir Fishman and held senior Investment Banking and Banking positions with Robertson Stephens/Evergreen, Poalim Capital Markets and Bank Hapoalim. Anat volunteers as lecturer and mentor in various organizations in the academia and the high -tech eco-system, with a strong emphasis on empowerment of women in the entrepreneurial community. Ms. Tsour Segal holds a BA in Economics and Management, MBA and L.L.B. from the Tel Aviv University.
Ron Mayron is the founder and CEO at RonMed Ltd. There he leads a company that consultants to healthcare companies, their core expertise are Mergers & Acquisitions, Integration and Implementation, Global Business Development, Global Operations & Supply Chain. Ron brings with him extensive, long-term experience in the local & global pharmaceutical and medical device arena. Before that Ron worked at Teva Pharmaceutical industries Ltd. for 21 years leaving as Vice President Israel & Africa & CEO Teva Israel. Ron is now serving as an active director for 9 different companies and has served at 6 others mainly in the healthcare, medical device, pharmaceutical and biotech fields. Ron has a M.B. A, from the University of Tel-Aviv; majored in information systems with secondary stream in Technology Management and Operational Systems, and a B.Sc. from the Industrial & Management Engineering, Ben-Gurion University of the Negev; majored in Information Systems.
Since 2009 Doron has been the CEO of Doron Birger Management and Consulting. He is the active chairman of a number of technology companies: Sight Diagnostic, Onsight, Nurami and Matricelf. From 2002-2007 Doron was the Chairman and Director in Given Imagine (Nasdaq/TASE-GIVN ) and director in Icecure (TASE:ICECURE), Heramed (ASX:HMD ), Citrine Global Corp. (OTCQB:CTGL), Vibrant and Netive Haor. Doron was a special consultant at Vimodo; a company that invests in the field of cancer research and treatment. Doron was also the CEO and Special consultant of Landmark Ventures Israel; a US hi- tech investment banking firm. From 2002-2009 Doron was the President and Chief Executive Officer of Elron Electronic Industries Ltd. There he advanced Elron as a leading high-tech group in Israel including 27 companies, 3 of them publicly traded, focused in the fields of Medical Devices, as well as communications, Software, Clean Tech and Semiconductors.
Mrs. Keren-Blum is a lawyer and notary, the owner of Tzlill Keren-Blum Law Office. Mrs. Keren-Blum serves as BlueStar Indexes' EMEA representative and as Director in Israeli public companies. Mrs. Keren-Blum has more than 15 years of experience in the financial industry. Mrs. Keren-Blum served as Chief Legal Counsel at the biggest ETF issuer in Israel and as an associate at one of the largest Israeli law firms, specializing in capital markets and banks. Mrs. Keren-Blum holds an Executive LL.M (Cum Laude) from Tel-Aviv University and Berkeley University (California), LL.B and BA (Economics) from Tel-Aviv University.
Ilan Hadar is the Chief Financial Officer, of Foamix Pharmaceuticals Ltd., since February 2014 and also Israel Country Manager since July 2017. Mr. Hadar has over 20 years of experience in executive financial positions, previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager, Accounting and Reporting, at the Israeli subsidiary of HP from 2007 to 2011, and, prior to that, as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a BA in business administration and economics, and an MBA from The Hebrew University of Jerusalem.
Advocate Ziv Ironi- Founder & owner of Ziv Ironi, Advocates & Notary Law Firm a boutique law firm located in Tel Aviv. Mr. Ironi has over 30 years of experience as a legal counselor specializing in the fields of corporate law, tenders law, contract law, labor law and land law. Mr. Ironi has served as a director for Otsar Mifalei Yam Ltd. and is currently serving as an active director of various companies, including and Arkia’s air lines Ltd. He served as an external director of Ultra Equity Ltd and as chairman of the board of Sport Palaces Ltd. Mr. Ironi is also a member of the Board of Trustees of the Tel Aviv Museum of Art. Ziv Ironi holds a Bachelor's degree (LL.B.) from Tel Aviv University, and holds a Master's degree (LL.M.) in Commercial Law from Tel Aviv University.